Douglas S. Boothe was the leader of a little-known generic-drug maker seven years ago when federal agents approached his company with an urgent plea: Slash production of an addictive pain medication that was fueling a national crisis. Boothe “wasn’t interested” and rejected the Drug Enforcement Administration’s request that Actavis voluntarily cut its supply of oxycodone […]